Current status and evolution of preclinical drug development models of epithelial ovarian cancer

by Panagiotis A Konstantinopoulos, Ursula A Matulonis
Published 2013-12-01

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies

by Elizabeth K. Lee, Ursula A. Matulonis
Published 2020-07-01

POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure

by Elizabeth K. Lee, Neal I. Lindeman, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos
Published 2019-05-01

An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers

by Ewa Przybytkowski, Thomas Davis, Abdelrahman Hosny, Julia Eismann, Ursula A. Matulonis, Gerburg M. Wulf, Sheida Nabavi
Published 2020-03-01

Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks

by Kun-Hsing Yu, Vincent Hu, Feiran Wang, Ursula A. Matulonis, George L. Mutter, Jeffrey A. Golden, Isaac S. Kohane
Published 2020-08-01

Open-Source, Step-Counting Algorithm for Smartphone Data Collected in Clinical and Nonclinical Settings: Algorithm Development and Validation Study

by Marcin Straczkiewicz, Nancy L Keating, Embree Thompson, Ursula A Matulonis, Susana M Campos, Alexi A Wright, Jukka-Pekka Onnela
Published 2023-11-01

High throughput interrogation of somatic mutations in high grade serous cancer of the ovary.

by Ursula A Matulonis, Michelle Hirsch, Emanuele Palescandolo, Eejung Kim, Joyce Liu, Paul van Hummelen, Laura MacConaill, Ronny Drapkin, William C Hahn
Published 2011-01-01

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer

by Elizabeth K. Lee, Zhenying Tan-Wasielewski, Ursula A. Matulonis, Michael J. Birrer, Alexi A. Wright, Neil Horowitz, Panagiotis A. Konstantinopoulos, Jennifer Curtis, Joyce F. Liu
Published 2019-08-01

Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression

by Brooke E. Howitt, Kyle C. Strickland, Lynette M. Sholl, Scott Rodig, Lauren L. Ritterhouse, Dipanjan Chowdhury, Alan D. D'Andrea, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos
Published 2017-02-01

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal...

by Elizabeth K. Lee, Zhenying Tan-Wasielewski, Carol Aghajanian, Robert L. Coleman, Jennifer Curtis, Michelle S. Hirsch, Ursula A. Matulonis, Lewis C. Cantley, Gordon B. Mills, L. Austin Doyle, Joyce F. Liu
Published 2020-05-01

Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.

by Nicolai Juul Birkbak, Bose Kochupurakkal, Jose M G Izarzugaza, Aron C Eklund, Yang Li, Joyce Liu, Zoltan Szallasi, Ursula A Matulonis, Andrea L Richardson, J Dirk Iglehart, Zhigang C Wang
Published 2013-01-01

BRAF and AXL oncogenes drive RIPK3 expression loss in cancer.

by Ayaz Najafov, Ioannis K Zervantonakis, Adnan K Mookhtiar, Patricia Greninger, Ryan J March, Regina K Egan, Hoang Son Luu, Daniel G Stover, Ursula A Matulonis, Cyril H Benes, Junying Yuan
Published 2018-08-01

Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer

by Panagiotis A. Konstantinopoulos, Niya Xiong, Carolyn Krasner, Joyce F. Liu, Hannah Sawyer, Madeline Polak, Hope Needham, Megan Geddes, Lani Koppermann, Meghan Shea, Cesar Castro, Su-Chun Cheng, Ursula A. Matulonis, Elizabeth K. Lee
Published 2024-04-01

Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer.

by Stefan Bentink, Benjamin Haibe-Kains, Thomas Risch, Jian-Bing Fan, Michelle S Hirsch, Kristina Holton, Renee Rubio, Craig April, Jing Chen, Eliza Wickham-Garcia, Joyce Liu, Aedin Culhane, Ronny Drapkin, John Quackenbush, Ursula A Matulonis
Published 2012-01-01

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer

by Liya Ding, Hye-Jung Kim, Qiwei Wang, Michael Kearns, Tao Jiang, Carolynn E. Ohlson, Ben B. Li, Shaozhen Xie, Joyce F. Liu, Elizabeth H. Stover, Brooke E. Howitt, Roderick T. Bronson, Suzan Lazo, Thomas M. Roberts, Gordon J. Freeman, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Jean J. Zhao
Published 2018-12-01

A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma

by Elizabeth H. Stover, Niya Xiong, Andrea P. Myers, Nabihah Tayob, Victoria Engvold, Madeline Polak, Russell R. Broaddus, Vicky Makker, Ronny Drapkin, Joyce F. Liu, Neil S. Horowitz, Funda Meric-Bernstam, Carol Aghajanian, Robert L. Coleman, Gordon B. Mills, Lewis C. Cantley, Ursula A. Matulonis, Shannon N. Westin, Panagiotis A. Konstantinopoulos
Published 2022-04-01

STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer

by Qiwei Wang, Johann S. Bergholz, Liya Ding, Ziying Lin, Sheheryar K. Kabraji, Melissa E. Hughes, Xiadi He, Shaozhen Xie, Tao Jiang, Weihua Wang, Jason J. Zoeller, Hye-Jung Kim, Thomas M. Roberts, Panagiotis A. Konstantinopoulos, Ursula A. Matulonis, Deborah A. Dillon, Eric P. Winer, Nancy U. Lin, Jean J. Zhao
Published 2022-05-01

Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient <i>TP53</i> Mutant Uterine Carcinomas Is Linked to the Summation of LKB1–AKT–p53 Interactions

by Katherine N. Lynch, Joyce F. Liu, Nikolas Kesten, Kin-Hoe Chow, Aniket Shetty, Ruiyang He, Mosammat Faria Afreen, Liping Yuan, Ursula A. Matulonis, Whitfield B. Growdon, Michael G. Muto, Neil S. Horowitz, Colleen M. Feltmate, Michael J. Worley, Ross S. Berkowitz, Christopher P. Crum, Bo R. Rueda, Sarah J. Hill
Published 2021-05-01

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13

by Mei Zeng, Nicholas P Kwiatkowski, Tinghu Zhang, Behnam Nabet, Mousheng Xu, Yanke Liang, Chunshan Quan, Jinhua Wang, Mingfeng Hao, Sangeetha Palakurthi, Shan Zhou, Qing Zeng, Paul T Kirschmeier, Khyati Meghani, Alan L Leggett, Jun Qi, Geoffrey I Shapiro, Joyce F Liu, Ursula A Matulonis, Charles Y Lin, Panagiotis A Konstantinopoulos, Nathanael S Gray
Published 2018-11-01

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

by Panagiotis A. Konstantinopoulos, Alexandre André B. A. da Costa, Doga Gulhan, Elizabeth K. Lee, Su-Chun Cheng, Andrea E. Wahner Hendrickson, Bose Kochupurakkal, David L. Kolin, Elise C. Kohn, Joyce F. Liu, Elizabeth H. Stover, Jennifer Curtis, Nabihah Tayob, Madeline Polak, Dipanjan Chowdhury, Ursula A. Matulonis, Anniina Färkkilä, Alan D. D’Andrea, Geoffrey I. Shapiro
Published 2021-09-01